CN114452308A

CN114452308A - Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent

Info

Publication number: CN114452308A
Application number: CN202110682975.7A
Authority: CN
Inventors: 田海宏; 胡文亮; 范东升; 田海涛; 何荣锋; 田胜利
Original assignee: Shanghai Shidao Intelligent Pharmaceutical Technology Co ltd
Current assignee: Shanghai Shidao Intelligent Pharmaceutical Technology Co ltd
Priority date: 2021-06-18
Filing date: 2021-06-18
Publication date: 2022-05-10

Abstract

The invention discloses a probiotic protective agent, a microecological preparation prepared from the same and application of the probiotic protective agent, wherein the probiotic protective agent comprises the following components: inulin, bamboo leaf extract, platycodon root powder and mulberry leaf powder. According to the invention, after the probiotics and the probiotics protective agent are mixed, the probiotics can be effectively protected, the survival rate and the planting rate of the probiotics after passing through the stomach and the intestinal tract are improved, meanwhile, the storage time of the probiotics is prolonged, the diarrhea is relieved and eliminated, the balance of intestinal microecology is adjusted, the proliferation of harmful intestinal bacteria is inhibited, and the level of inflammatory factors in the body of a patient suffering from chronic enteritis can be reduced.

Description

Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent

Technical Field

The invention relates to a probiotic protective agent, a microecological preparation prepared from the same and application of the probiotic protective agent.

Background

The intestinal tract is an important place for human digestion and absorption, and is also the largest immune organ of the human body, and is called as the second brain of the human body by research because of the widely distributed nervous system in the intestinal tract.

Microorganisms in the human intestinal tract help people to complete various physiological and biochemical functions. Over 1000 intestinal microorganisms are known, which account for about 80% of the human microbial mass, while their mass is only 1.5-2 kg.

In recent years, many studies show that the intestinal flora is closely related to the health condition of human body, and closely influences various aspects of nutrient absorption, substance metabolism, immunity, gastrointestinal development and the like of a host, and factors such as the genotype, age, immune system and the like of the host play an important role in the formation and the stability of the intestinal flora structure. In this case, the intestinal micro-ecology is particularly important.

The total length of human intestinal tract is about 9 m, and the surface area is over 300m²The total number of bacteria living in the intestinal tract is about 10 times of the total number of human cells, and the growth and propagation of bacteria in the gastrointestinal tract, the living metabolism and the stability of the whole microbial environment all affect the health state of the gastrointestinal tract and even the whole body of the human body.

Researches show that the dietary structure and the nutrient intake are the most main factors for shaping the structure of the intestinal flora, and on one hand, the dietary structure and the nutrient intake can change the structure of the intestinal flora; on the other hand, the components which are difficult to be absorbed by human body in the food exert the nutrition function through the function of intestinal flora. More and more researches show that the probiotic effect of probiotics on human bodies is widely concerned by people, and mainly shows that the probiotics and pathogenic bacteria compete for binding sites and substrates, so that the balance of intestinal flora and the health of intestinal tracts of people are maintained; but also affects the secretion of microorganisms and host metabolites in the gut, thereby reducing the gut milieu, providing energy, reducing bacterial translocation, and reducing endotoxemia.

Although many studies with enzymes or probiotics have shown that the intestinal flora can be improved to some extent, reducing the proportion of pathogenic microorganisms. However, most of the existing probiotics easily lose activity in the processes of processing, transportation and shelf life storage, are difficult to maintain long-term stability, or enter the gastrointestinal tract of a human body and are killed or apoptotic greatly after contacting with the human body environment such as gastric acid, bile or digestive juice, and the effect of the probiotics is weakened.

Disclosure of Invention

The present disclosure provides a probiotic protectant, comprising inulin, bamboo leaf extract, platycodon grandiflorum powder and mulberry leaf powder.

In some embodiments, it further comprises emblic leafflower fruit powder.

In some embodiments, it further comprises sea buckthorn flour.

In some embodiments, the mass ratio of the inulin, the bamboo leaf extract, the platycodon root powder and the mulberry leaf powder is 1-4: 1-4.

In some embodiments, the weight ratio of the emblic leafflower powder to the inulin, the bamboo leaf extract, the platycodon root powder and the mulberry leaf powder is 1-4: 1-4.

In some embodiments, the weight ratio of the emblic leafflower powder to the inulin, the bamboo leaf extract, the platycodon root powder and the mulberry leaf powder is 3:2 or 3:2:3:1: 3.

In some embodiments, the mass ratio of the sea buckthorn powder to the emblic leafflower powder, the inulin, the bamboo leaf extract, the platycodon root powder and the mulberry leaf powder is 1-4: 1-4.

In some embodiments, the mass ratio of the sea buckthorn powder to the emblic leafflower powder, the inulin, the bamboo leaf extract, the platycodon root powder and the mulberry leaf powder is 2:1: 4:1 or 1: 1.

The present disclosure also provides a probiotic formulation comprising a probiotic and the probiotic protectant described above.

In some embodiments, wherein the probiotic is a lactobacillus species and/or a bifidobacterium species.

In some embodiments, wherein the probiotic is one or more of the following and combinations of probiotics: streptococcus thermophilus, Lactobacillus buchneri, Bifidobacterium longum, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus reuteri or Bifidobacterium breve.

In some embodiments, the probiotic preparation further comprises a fruit and vegetable fermented product, preferably the fruit and vegetable fermented product is selected from fruit and vegetable fermented dry powder, fruit and vegetable fermented juice, fruit and vegetable juice concentrated solution, fruit and vegetable juice raw pulp and fruit and vegetable fermented particles.

In some embodiments, the mass ratio of the probiotics to the probiotic protective agent is 1: 0.5-100.

In some embodiments, the mass ratio of the dry powder to the probiotic protective agent after the probiotics and the fruit and vegetable fermented dry powder are mixed is 1: 0.5-100, and the activity of the probiotics is more than 10⁶CFU/g, greater than 10⁷CFU/g, greater than 10⁸CFU/g, greater than 10⁹CFU/g, greater than 10¹⁰CFU/g or greater than 10¹¹CFU/g。

In some embodiments, the probiotic is in a solid or liquid state.

In some embodiments, the use of the probiotic for the preparation of a medicament for regulating the intestinal microecological balance in humans.

In some embodiments, the modulating the human intestinal microecological balance comprises inhibiting proliferation of intestinal deleterious bacteria, optionally comprising shigella, salmonella, pneumophilus, pseudomonas aeruginosa, staphylococcus aureus, and the like.

In some embodiments, the modulating the human intestinal microecological balance comprises decreasing the level of an inflammatory factor. The inflammatory factors comprise inflammatory factors related to intestinal chronic inflammation, such as IL-1, IL-6, IL-8, IL-12, IL-17, TNFa, CRP and the like.

Detailed Description

Term

In order that the disclosure may be more readily understood, certain technical and scientific terms are specifically defined below. Unless otherwise specifically defined herein, all other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

The "probiotics" in the present disclosure refers to a class of active microorganisms beneficial to a host by changing the flora composition of a certain part of the host through colonization in a human body. The intestinal health-care function is realized by regulating the immune function of a host mucous membrane and a system or regulating the flora balance in the intestinal tract, and the nutrition absorption is promoted, so that the single microorganism or the mixed microorganism with definite composition which is favorable for the health is generated. In particular pathological conditions, when the proportion of individual probiotics is severely unbalanced, it may also become a negative impact on the human mucosa or immune function, even cause diseases.

The existing probiotic bacteria mainly include Lactobacillus and Bifidobacterium, including but not limited to Streptococcus thermophilus (Streptococcus thermophilus), Lactobacillus buchneri (Lactobacillus buchneri), Bifidobacterium longum (Bifidobacterium longum), Lactobacillus paracasei (Lactobacillus paracasei), Lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus rhamnosus (Lactobacillus rhamnosus), Lactobacillus fermentum (Lactobacillus fermentum), Lactobacillus helveticus (Lactobacillus helveticus), Lactobacillus reuteri (Lactobacillus reuteri), and Bifidobacterium breve (Bifidobacterium breve).

The fermented dry powder of fruits and vegetables is prepared by pulverizing edible part, mixing, fermenting with yeast or other probiotics, and dewatering. The fruit and vegetable fermented product can be provided in the form of dry powder, and can also exist in the forms of fruit and vegetable fermented particles, fruit and vegetable juice, fruit and vegetable concentrated juice, fruit and vegetable raw juice and the like. The fruit and vegetable leavening is not a core functional component of the probiotic protective agent or the microecological preparation, and has the functions of providing an orally-taken carrier for probiotics and providing certain energy and nutrient substances for gastrointestinal flora. When the user is a person who does not need to increase sugar-containing substances such as diabetes, the microecological preparation may not contain fruit and vegetable leavening.

Fresh fruits and/or vegetables include, but are not limited to, one or more of peach, apple, pear, kiwi, pineapple, lemon, orange, tangerine, orange, coconut, cantaloupe, papaya, tomato, hawthorn, jujube, wolfberry, longan, lychee, rambutan, passion fruit, loquat, banana, watermelon, strawberry, cranberry, citrus, grapefruit, durian, wax apple, pomegranate, mulberry, blueberry, grape, mango, mangosteen, snake fruit, raspberry carrot, spinach, sword bean, cowpea, lettuce, sugar beet, tomato, cucumber, tremella, agaric, cabbage, celery, leek, and the like.

The traditional Chinese medicine extract disclosed by the invention is based on the principle that the constitutional features of inflammatory reaction are in accordance with the same regulation of three organs of liver, spleen and kidney in the theory of traditional Chinese medicine, and utilizes active ingredients in the medicinal and edible Chinese herbal medicine, so that on one hand, the body wet factor is adjusted, on the other hand, the microbial balance is adjusted, and the activity of beneficial bacteria in intestinal tracts is kept. The intestinal tract factor regulating effect of traditional Chinese medicine is utilized, and the probiotic bacteria are utilized to regulate the intestinal tract microecological balance, so that the harmful bacteria in the intestinal tract are inhibited and eliminated, the intestinal tract factor is eliminated, and the level of the intestinal tract inflammatory factor is reduced. The following medicines are selected for compatibility:

the chrysanthemum, pungent, sweet, bitter and slightly cold, enters lung and liver channels and has the effects of dispelling wind and clearing heat, calming liver and improving eyesight and detoxifying.

The emblic leafflower fruit is sweet, sour, astringent and cool, enters lung, spleen and stomach channels, and has the effects of detoxifying and relieving sore throat, clearing heat and promoting fluid, moistening lung and reducing phlegm.

The bamboo leaves, sweet, pungent, bland and cold, enter heart, lung and stomach meridians, and have the effects of clearing heat, relieving restlessness, promoting fluid production and promoting urination.

Platycodon grandiflorum, bitter, pungent and even in flavor, enters lung meridian, and has the effects of dispersing lung qi, eliminating phlegm, relieving sore throat, expelling pus and opening lung qi.

Mulberry leaf, bitter, sweet and cold, entering lung and liver meridian, has the functions of dispelling wind and heat, calming liver, improving eyesight, clearing lung, moistening dryness, cooling blood and stopping bleeding.

Sea buckthorn is sour, astringent and warm, enters lung, stomach, spleen and heart meridians, and has the effects of strengthening spleen to promote digestion, relieving cough and eliminating phlegm, and activating blood circulation to dissipate blood stasis.

The compatibility of medicines has the following meanings: the intestinal environment is usually damp-heat. Modern people have good dietary conditions, more animal food intake, more mental labor, sedentariness, excessive thinking and the like, and the intestinal environment is more humid and hot. In order to assist in conditioning intestinal flora balance, extracts of bamboo leaves, phyllanthus emblica, platycodon grandiflorum, sea buckthorn, chrysanthemum and mulberry leaves are used for adjusting intestinal micro-ecology of a human body. Besides being used as a probiotic protective agent, the traditional Chinese medicine composition also participates in the mediation of intestinal microbial flora. Eliminating dampness of the bamboo leaves; fructus Phyllanthi, radix Platycodi and fructus Hippophae for eliminating phlegm; the chrysanthemum and the mulberry leaf are wind drugs which can disperse heat and dispel dampness. Meanwhile, the cold-temperature balance of a plurality of medicines is considered, and a complete formula is formed.

The inulin, the platycodon root powder, the mulberry leaf powder, the sea buckthorn powder, the bamboo leaf extract and the emblic leafflower fruit powder are powdery particles obtained by decocting the traditional Chinese medicine decoction pieces with water at 100 ℃ and then performing ultrasonic drying on the extract. Or by extracting and preparing by conventional preparation method of Chinese medicinal granule.

The intestinal harmful bacteria refer to bacteria or actinomycetes or fungi which can cause diseases and invade the intestinal tract of the human body. Including but not limited to shigella, salmonella, pneumobacillus, pseudomonas aeruginosa, staphylococcus aureus, etc.

"administration" and "treatment," when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, refers to contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with the animal, human, subject, cell, tissue, organ, or biological fluid. "administration" and "treatment" may refer to, for example, therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. The treatment of the cells comprises contacting the reagent with the cells and contacting the reagent with a fluid, wherein the fluid is in contact with the cells. "administering" and "treating" also mean treating, for example, a cell in vitro and ex vivo by a reagent, a diagnostic, a binding composition, or by another cell. "treatment" when applied to a human, veterinary or research subject refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.

By "treating" is meant administering a therapeutic agent, e.g., a composition comprising any one of the binding compounds of the present disclosure, either internally or externally to a patient who has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, the therapeutic agent is administered in the subject patient or population in an amount effective to alleviate one or more symptoms of the disease, to induce regression of such symptoms or to inhibit development of such symptoms to any clinically measurable degree. The amount of therapeutic agent effective to alleviate the symptoms of any particular disease (also referred to as a "therapeutically effective amount") may vary depending on a variety of factors, such as the disease state, age, and weight of the patient, and the ability of the drug to produce a desired therapeutic effect in the patient. Whether a disease symptom has been reduced can be assessed by any clinical test commonly used by physicians or other health professional to assess the severity or progression of the symptom. Although embodiments of the present disclosure (e.g., methods of treatment or articles of manufacture) may be ineffective in alleviating the symptoms of each target disease, they should alleviate the symptoms of the target disease in a statistically significant number of patients as determined according to any statistical test method known in the art, such as the student test, chi-square test, U-test by Mann and Whitney, Kruskal-Wallis test (H-test), jonckhere-Terpstra test, and Wilcoxon test.

On one hand, the probiotic protective agent provided by the invention can protect the probiotics from the gastrointestinal environment of organisms such as gastric acid and bile salt in vivo and in vitro, increase the survival rate and the planting rate of the probiotics and enable the probiotics to effectively play the effect of balancing intestinal flora; on the other hand, the pharmaceutical composition can also regulate the damp-heat environment of the intestinal tract of the organism. The probiotics protective agent, probiotics and the microecological preparation formed by the fruit and vegetable fermentation powder can reduce intestinal inflammatory factors, assist the balance of intestinal flora, and realize the effects of eliminating diarrhea, constipation and the like.

Second, example and test

The present disclosure is further described below with reference to examples, but these examples do not limit the scope of the present disclosure. The experimental method of the embodiment of the present disclosure, which is not indicated for specific conditions, is generally performed according to conventional conditions; or according to the conditions recommended by the manufacturer of the raw material or the goods. Reagents of specific sources are not indicated, and conventional reagents are purchased in the market.

Example 1 preparation of probiotic protectant

Taking 12g of the probiotic protective agent as a unit, weighing 12g of powdered inulin, emblic leafflower fruit powder, lophatherum gracile extract, platycodon root powder, mulberry leaf powder and/or sea buckthorn powder, and uniformly mixing, wherein the specific experimental examples and comparative examples have the component dosage shown in table 1 in detail.

Table 1 probiotic bacteria protective agent component proportion relation table of experimental examples

Table 1 shows that the probiotic protective agent in each experimental example or comparative example is sterilized, sealed and stored at 4 ℃.

Example 2 accelerated verification test of Probiotics protection rate by Probiotics protectant

In order to verify the storage and protection effect of the probiotic protective agent on probiotics, 2g of each probiotic protective agent is mixed with 5ml of purified water, and then the mixture is respectively mixed with fruit and vegetable fermented dry powder containing the probiotics, wherein the fruit and vegetable fermented dry powder comprises:

2g of fruit and vegetable fermented dry powder containing bifidobacterium longum (ATCC.55813);

2g of fruit and vegetable fermented dry powder containing streptococcus thermophilus (ATCC.19258);

2g of fruit and vegetable fermented dry powder containing lactobacillus rhamnosus (ATCC.7469);

or 1g of fermented dry fruit and vegetable powder containing Lactobacillus fermentum (ATCC.11739) and 1g of fermented dry fruit and vegetable powder containing Lactobacillus helveticus (ATCC.15009).

And respectively and fully mixing the probiotic protective agent solution with the probiotic-containing fruit and vegetable fermented dry powder uniformly, freeze-drying the mixture to form dry powder, and hermetically storing the dry powder without other mixed bacteria. Placing in a drying oven environment at 37 deg.C for 3 months to accelerate the simulation of long-term storage environment of probiotics. 5 samples are set for each probiotic, and the activity of each probiotic sample is determined to be 9.0 multiplied by 10 before the test⁹CFU/g or above. Finally, the activity protection rate of each experimental example to probiotics is calculated as (activity of probiotics after test/activity of probiotics before test) x 100%, and the activity protection rate of each probiotic is averaged. Finally, the activity protection rate of each experimental example on different probiotics is shown in table 2.

TABLE 2 Protect rate of probiotic activity in each experimental example

Through an accelerated verification test of the probiotic protective agent on the probiotic protection rate, the traditional Chinese medicine extract added in each experimental example has better protection efficiency than glucan under a dry storage condition, and the experimental examples 3-7 have no significant statistical difference except that the protection rates of the experimental example 1 and the experimental example 2 are slightly lower than those of the experimental examples 3-7.

Example 3 probiotic protectant Rate of Protection of probiotics in simulated gastric acid Environment

In order to verify the protection effect of the probiotic protective agent on probiotics in a gastric acid environment, 2g of each probiotic protective agent is mixed with 4ml of purified water, then the mixture is respectively and fully mixed with 2g of fruit and vegetable fermented dry powder containing lactobacillus paracasei or 2g of bifidobacterium longum, the mixture is added into 20ml of HCl solution with the pH value of 2.0, the mixture is placed in a 37 ℃ incubator environment and is placed for 2 hours, and the activity preservation condition of the probiotics in the gastric acid environment is simulated. 3 samples are set for each probiotic, and the activity of each probiotic sample is determined to be 9.0 multiplied by 10 before the test⁹CFU/g or above. The activity protection rate for each experimental example against probiotics (post-test probiotic activity/pre-test probiotic activity) was finally calculated as 100%, and the activity protection rate for each probiotic was averaged. The protection rate of each experimental example for different probiotics activity is detailed in table 3.

Table 3 protection rate of probiotic activity under simulated gastric acid conditions in each experimental example

Experimental example 1

Experimental example 2

Experimental example 3

Experimental example 4

Experimental example 5

Experimental example 6

Experimental example 7

Comparative example

Lactobacillus paracasei

27.6％

29.4％

32.4％

20.7％

25.7％

33.4％

30.2％

8.7％

Bifidobacterium longum

31.8％

27.3％

29.7％

29.4％

33.1％

31.6％

35.9％

10.4％

A test for verifying the protection rate of the probiotic protective agent on probiotics in a simulated gastric acid environment shows that the probiotic protective agent consisting of the traditional Chinese medicine extract can more effectively resist the influence of gastric acid on the activity of the probiotics compared with glucan.

Example 4 test of the Effect of Probiotics protective Agents on intestinal Microecology in a mouse diarrhea model

In order to verify the protection effect of the probiotic protective agent on probiotics and the regulation effect of intestinal flora, a mouse diarrhea model is adopted for verification.

Preparing a mixture of probiotics and a probiotic protective agent (namely a microecological mixed solution): 1g of fruit and vegetable fermented dry powder containing bifidobacterium longum, 1g of lactobacillus fermentum and 1g of lactobacillus helveticus is mixed with 2g of the probiotic protective agent in each experimental example, 10ml of purified water is added, and the mixture is fully mixed to form a micro-ecological mixed solution.

Establishing a mouse diarrhea model by referring to the method of Zhao Yangling et al (2009), taking diarrhea mice (SPF grade C57BL mice, Beijing Weitongli laboratory animal technology Co., Ltd.), setting experimental examples 3-7 groups and comparative example groups, and a negative control group (no feeding of a micro-ecological mixed solution) and a normal control group (no feeding of any diarrhea or micro-ecological solution intervention, only providing normal feeding conditions), each group comprising 10 animals, each half of male and female, and feeding about 10 animals on the first day and the second day after the model is established⁹In the case of normal diet, salmonella of cells was gavaged with the mixed micro-ecological solutions of different experimental examples from the third day, 0.8 ml/day per mouse, continuously fed for 7 days, and the negative control group was replaced with physiological saline.

Mice were observed daily for activity and fecal characteristics. Mice were sacrificed on day 10 of the experiment and intestinal contents were taken, and negative controls, if dead within 10 days, taken intestinal contents and extracted contents DNA in time. And detecting the relative abundance of the intestinal microorganisms of the mice, and extracting the content DNA of the small intestines of the mice on the tenth day by adopting a QIAamp Fast DNA Stool Mini Kit according to the instruction. The Jinzhi Biotechnology Limited company is entrusted to detect the 16S rDNA of the intestinal microorganisms and analyze the relative abundance of the intestinal microorganisms.

After the model mice are fed by the micro-ecological mixed solution, the diarrhea phenomenon is obviously improved, 5 mice in a negative control group die before the 10 th day of the experiment, 1 mouse in a comparative control group die at the 7 th day of the experiment, and no mouse in other groups dies. On day 5, the average body weight of the mice in the negative control group was significantly lower than that in each of the experimental group, the control group, and the normal control group.

According to analysis of relative abundance of microorganisms in intestinal tracts of mice, the addition of the probiotics can obviously inhibit proliferation of salmonella in the intestinal tracts and eliminate symptoms of diarrhea through inhibition of pathogenic bacteria. In each experimental example group containing different combinations of traditional Chinese medicine extracts, the probiotic protective agent can more effectively protect the survival and the colonization of probiotics in the intestinal tracts of model mice compared with glucan.

TABLE 4 Experimental day 10 relative abundance of intestinal microbes in each group of mice

EXAMPLE 5 Effect of the Microecologic Mixed solution on the Elimination of inflammatory factors in patients with Chronic enteritis

In order to verify the protection of the probiotic protective agent on the human body and the regulation effect of the micro-ecological mixed solution on the intestinal inflammatory reaction of the human body, the inflammatory factor and diarrhea regulation effect of volunteers with chronic enteritis are verified.

15 volunteers with chronic enteritis and active were enrolled and carried out after signing informed consent and privacy agreements. The 15 volunteers all had chronic diarrhea and had defecation 4-6 times per day. Pale-red or pale-purple tongue with white and greasy coating and soft-superficial pulse.

Preparing a mixture of probiotics and a probiotic protective agent (namely a microecological mixed solution): each dose of the probiotic protecting agent is prepared by mixing 0.5g of fruit and vegetable fermented dry powder containing bifidobacterium longum, 0.5g of lactobacillus paracasei and 0.5g of lactobacillus helveticus with 15g of the probiotic protecting agent in experimental example 5 or experimental example 7, adding 15ml of warm water (about 45 ℃), and fully and uniformly mixing to form a microecological mixed solution. Of these, 7 volunteers took the mixed micro-ecological solution containing experimental example 5 (experimental example 5 group), and 8 volunteers took the mixed micro-ecological solution containing experimental example 7 (experimental example 7 group).

One dose of the micro-ecological mixed solution is taken by each person in the morning and evening for 14 days continuously. Inquiring the defecate, sleep and hypodynamia of the patient, collecting venous blood on the 0 th day and the 14 th day of taking the micro-ecological mixed solution for the first time respectively, separating serum, and detecting the levels of inflammatory factors such as IL-1, IL-6, IL-8, TNF-alpha, CRP and the like in the serum of the patient.

TABLE 5 comparison of serum inflammatory factor levels (x. + -.s) in patients with chronic enteritis

Note: p < 0.05 compared to day 0, and P < 0.05 compared to day 14 in group of Experimental example 5.

After 14 days of conditioning, the diarrhea symptoms of two groups of chronic enteritis patients are effectively relieved, and the stool frequency is changed into 1-2 times per day. In each of the groups of experiment example 5 and experiment example 7, 5 patients had improved feelings of fatigue, 3 patients in the group of experiment example 5 had improved quality of sleep, and 5 patients in the group of experiment example 7 had improved quality of sleep.

Although the foregoing invention has been described in some detail by way of illustration for purposes of clarity of understanding, the description and examples should not be construed as limiting the scope of the disclosure. The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entirety.

Claims

1. A probiotic protectant, comprising: inulin, bamboo leaf extract, platycodon root powder and mulberry leaf powder.

2. The probiotic protectant of claim 1, further comprising: emblic leafflower fruit powder.

3. The probiotic protectant according to any of claims 1 or 2, further comprising: sea-buckthorn powder.

4. The probiotic protective agent according to claim 1, wherein the mass ratio of the inulin, the bamboo leaf extract, the platycodon root powder and the mulberry leaf powder is 1-4: 1-4.

5. The probiotic protectant according to claim 2, wherein the mass ratio of the emblic leafflower powder to the inulin, the bamboo leaf extract, the platycodon root powder and the mulberry leaf powder is one of the following: 1-4: 1-4, 3:3:2:2:2 or 3:2:3:1: 3.

6. The probiotic protectant of claim 2, further comprising: the sea buckthorn powder, the emblic leafflower fruit powder, the inulin, the bamboo leaf extract, the platycodon root powder and the mulberry leaf powder are in a mass ratio relation of one of the following: 1-4: 1-4, 2:1:1:4:1:1 or 1:1:1:1: 1.

7. A microecological formulation which comprises: a probiotic and a probiotic protectant according to any of claims 1 to 6.

8. The probiotic of claim 7, wherein the probiotic comprises: at least one of Lactobacillus and Bifidobacterium.

9. The probiotic of claim 7, comprising at least one of the following: streptococcus thermophilus, Lactobacillus buchneri, Bifidobacterium longum, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus reuteri or Bifidobacterium breve.

10. Use of a probiotic according to any one of claims 7 to 9 for the preparation of a preparation for regulating the intestinal microecological balance in humans.